January 31, 2018 / 12:06 PM / 7 months ago

BRIEF-Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial Of Korsuva Injection

Jan 31 (Reuters) - Cara Therapeutics Inc:

* CARA THERAPEUTICS INITIATES PIVOTAL PHASE 3 EFFICACY TRIAL OF KORSUVA™ (CR845/DIFELIKEFALIN) INJECTION IN HEMODIALYSIS PATIENTS WITH CHRONIC KIDNEY DISEASE-ASSOCIATED PRURITUS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below